SCHEMBL4484050

SCHEMBL4484050

Cn1c(C(=O)N2CCOCC2)c2c(c(O)c1=O)C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2C19 P33261 2/20 0.41
GAA P10253 1/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CA P42336 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 3/20 0.37
PKM P14618 1/20 0.37
AKT1 P31749 1/20 0.37
PIK3CG P48736 1/20 0.37
LMNA P02545 1/20 0.36
PARP1 P09874 1/20 0.36
CYP2C9 P11712 1/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
RAD51 Q06609 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483969 0.92 PREP (0.37) SMN1; SMN2MAPTALDH1A1PARP1
SCHEMBL4492862 0.91 AKR1B1 (0.34) SMN1; SMN2CYP3A4CYP2C19ALDH1A1
SCHEMBL4490676 0.90 HTR1A (0.34)
SCHEMBL13672787 0.87 AKR1B1 (0.38) SMN1; SMN2PIK3CAALDH1A1
SCHEMBL5446552 0.85 POLB (0.38) POLB
SCHEMBL4478160 0.85 MEN1 (0.39) SMN1; SMN2CYP2C19MAPTALDH1A1PKM
SCHEMBL31060990 0.85 AKR1B1 (0.36) PIK3CBPIK3CA
SCHEMBL4479511 0.85 AKR1B1 (0.36) PIK3CBPIK3CA
SCHEMBL4480852 0.84 CENPE (0.36) SMN1; SMN2MAPTKDM4E
SCHEMBL4488414 0.84 AKR1B1 (0.35) PIK3CBPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H SMN1; SMN2 4492/4885CYP3A4 327/4885CYP2C19 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.